House Members Object To Senate Adding Supplement MPL Proposal In FDA User Fee Bill
Executive Summary
Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.
You may also be interested in...
US VMS Industry Makes Lame Duck Session List, Checks It Twice For MPL Language
AHPA urges chairs and ranking members of Senate HELP and House Energy and Commerce committees not to pass mandatory product listing legislation or make other changes to FDA regulation of industry before the 117th Congress ends. NPA board members lobby lawmakers about the topic.
CHPA Urges NIH Office of Dietary Supplements To ‘Educate’ Congress, FDA On Label Database
With Congress considering mandatory supplement product listing as requested by FDA, trade group asks NIH’s Office of Dietary Supplements to share its experience building and maintaining its label database.
Cosmetics Industry Still Committed To Reg Modernization, But FDA User-Fee Reauthorization May Not Be Vehicle
A “clean” FDA user-fee reauthorization bill – minus cosmetics modernization provisions – could be the likeliest way forward with user-fee program funding set to elapse at the end of September, a PCPC rep suggested in an email to HBW Insight.